BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Azura Ophthalmics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

  November 23, 2020

   · 

  1 min read
• Biotech Beach

  Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH)

  November 23, 2020

   · 

  5 min read
• Biotech Bay

  eHealth, Inc. to Present at Evercore ISI HealthCONx Conference

  eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance marketplace, today announced that its management will present at the Third Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 2:40 p.m. E.T.

  November 23, 2020

   · 

  1 min read
• FDA

  FDA Approves First Drug to Treat Rare Metabolic Disorder

  Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder.

  November 23, 2020

   · 

  3 min read